Trial Profile

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belantamab mafodotin (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Adverse reactions
Acronyms DREAMM-9
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

13 Mar 2025 Planned primary completion date changed from 15 Nov 2024 to 2 Jun 2025.
13 Mar 2025 Status changed from recruiting to active, no longer recruiting.
17 May 2024 Planned End Date changed from 3 Nov 2025 to 2 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com